Literature DB >> 22221785

Bone loss and avascular necrosis of bone after hematopoietic cell transplantation.

Brian McClune1, Navneet S Majhail, Mary E D Flowers.   

Abstract

Advances in transplantation technology and supportive care measures have resulted in significant decrease in early mortality resulting in continued growth in the number of long-term hematopoietic cell transplantation (HCT) survivors. The intensity of chemotherapy and total body irradiation regimen used pretransplantation to eradicate the primary disease can lead to organ toxicities, including significant bone complications after HCT. Bone loss is frequent in HCT recipients and results from impaired bone mineralization through disturbances of calcium and vitamin D homeostasis, osteoblast and osteoclast dysfunction, and deficiencies in growth or gonadal hormone secretion. Exposure to glucocorticoids and calcineurin inhibitors for prevention and treatment of graft-versus-host disease (GVHD) represents one of the major causes for the increased risk of osteoporosis and avascular necrosis of bone (AVN) in recipients of allogeneic HCT. In this article we review the incidence, pathogenesis, and risk factors for osteoporosis and AVN after allogeneic HCT and discuss general guidelines for their treatment and monitoring based on the limited available reports.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22221785     DOI: 10.1053/j.seminhematol.2011.10.007

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  6 in total

1.  Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents.

Authors:  Xiaxin Li; Ruta Brazauskas; Zhiwei Wang; Amal Al-Seraihy; K Scott Baker; Jean-Yves Cahn; Haydar A Frangoul; James L Gajewski; Gregory A Hale; Jack W Hsu; Rammurti T Kamble; Hillard M Lazarus; David I Marks; Richard T Maziarz; Bipin N Savani; Ami J Shah; Nirali Shah; Mohamed L Sorror; William A Wood; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-02       Impact factor: 5.742

Review 2.  The cellular composition and function of the bone marrow niche after allogeneic hematopoietic cell transplantation.

Authors:  Flavia Peci; Linde Dekker; Anna Pagliaro; Ruben van Boxtel; Stefan Nierkens; Mirjam Belderbos
Journal:  Bone Marrow Transplant       Date:  2022-06-11       Impact factor: 5.174

3.  Late effects in hematopoietic cell transplant recipients with acquired severe aplastic anemia: a report from the late effects working committee of the center for international blood and marrow transplant research.

Authors:  David Buchbinder; Diane J Nugent; Ruta Brazauskas; Zhiwei Wang; Mahmoud D Aljurf; Mitchell S Cairo; Robert Chow; Christine Duncan; Lamis K Eldjerou; Vikas Gupta; Gregory A Hale; Joerg Halter; Brandon M Hayes-Lattin; Jack W Hsu; David A Jacobsohn; Rammurti T Kamble; Kimberly A Kasow; Hillard M Lazarus; Paulette Mehta; Kasiani C Myers; Susan K Parsons; Jakob R Passweg; Joseph Pidala; Vijay Reddy; Carmen M Sales-Bonfim; Bipin N Savani; Adriana Seber; Mohamed L Sorror; Amir Steinberg; William A Wood; Donna A Wall; Jacek H Winiarski; Lolie C Yu; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2012-08-01       Impact factor: 5.742

4.  Factors influencing the late phase of recovery after bone mineral density loss in allogeneic stem cell transplantation survivors.

Authors:  P Anandi; N A Jain; X Tian; C O Wu; P A Pophali; E Koklanaris; S Ito; B N Savani; J Barrett; M Battiwalla
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

5.  Accelerated bone mass senescence after hematopoietic stem cell transplantation.

Authors:  B Serio; L Pezzullo; R Fontana; S Annunziata; R Rosamilio; M Sessa; V Giudice; I Ferrara; M Rocco; G De Rosa; P Ricci; L Tauchmanovà; N Montuori; C Selleri
Journal:  Transl Med UniSa       Date:  2013-01-04

Review 6.  Late effects of blood and marrow transplantation.

Authors:  Yoshihiro Inamoto; Stephanie J Lee
Journal:  Haematologica       Date:  2017-02-23       Impact factor: 9.941

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.